Public disclosure of inside information according to article 17 MAR

Biofrontera AG: Capital increase resolved in January 2023 will not be implemented

Leverkusen, Germany (pta037/24.07.2023/23:45 UTC+2)

Due to the current stock market price of the Biofrontera AG share, the Management Board has decided, with the consent of the Supervisory Board, not to implement the capital increase against cash contributions resolved by the General Meeting on 9 January 2023 and to withdraw the application for approval of a corresponding securities prospectus. In the capital increase resolution, the General Meeting specified a subscription price of EUR 1.05, at which the implementation of the capital increase does not appear possible given the current market development.

The Management Board


Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Contact Person: Investor Relations
Phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate